Voss Jan Oliver, Kühl Jörg-Sven, Holm Maike, Hauptmann Kathrin, Adolphs Nicolai
Department of Oral and Maxillofacial Surgery, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.
Department of Pediatric Hematology, Oncology, Hemostaseology, University Hospital Leipzig, Leipzig, Germany.
Ann Maxillofac Surg. 2018 Jul-Dec;8(2):303-306. doi: 10.4103/ams.ams_41_18.
Allogeneic hematopoietic stem cell transplantation (HSCT) is an established therapy and is without alternative for certain groups of patients. Successful HSCT induces both long-lasting remission and tolerance without the need for further immunosuppression. In this case, cellular repair and regenerative processes work in a physiologic manner allowing elective surgical procedures, such as the interdisciplinary correction of dentofacial anomalies. Here, we report the successful management of transverse maxillary deficiency by transpalatal distraction and subsequent orthodontic treatment in a 12-year-old boy who underwent HSCT for high-risk acute lymphoblastic leukemia at 5 years of age.
异基因造血干细胞移植(HSCT)是一种成熟的治疗方法,对于某些患者群体而言没有其他替代方案。成功的HSCT可诱导持久缓解和耐受,无需进一步免疫抑制。在这种情况下,细胞修复和再生过程以生理方式起作用,允许进行择期外科手术,例如牙颌面畸形的多学科矫正。在此,我们报告了一名12岁男孩经腭中缝牵张及后续正畸治疗成功矫治上颌横向发育不足的病例,该男孩5岁时因高危急性淋巴细胞白血病接受了HSCT。